Literature DB >> 18255190

JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1.

Elena Tamagno1, Michela Guglielmotto, Luca Giliberto, Antonella Vitali, Roberta Borghi, Riccardo Autelli, Oliviero Danni, Massimo Tabaton.   

Abstract

The activity of beta-secretase (BACE1), the endo-protease essential for the production of amyloid beta (Abeta) peptides, is increased in brain of late-onset sporadic Alzheimer's disease (AD), and oxidative stress is the potential cause of this event. Oxidative stress up-regulates the expression and the activity of BACE1 in cellular and animal models, through a mechanism that involves the increase of gamma-secretase cleavage on APP and the activation of c-jun N-terminal kinase/activator protein 1 (JNK/AP1) pathway. We further characterized the cellular pathways that control BACE1 expression under oxidative stress. We investigated the involvement of extracellular signal regulated MAP kinase (ERK1/2) pathway in the regulation of BACE1 expression, since it has been recently shown that ERK1/2 is an endogenous regulator of the gamma-secretase activity. We found that ERK1/2 pathway negatively modulates BACE1 expression and activity. Moreover, we observed that conditions that abrogate the gamma-secretase activity favor the activation of signalling pathways that promote cell survival, such as ERK1/2 and the serine/threonine kinase Akt/protein kinase B (Akt). These data suggest that the positive or negative cellular responses to oxidative stress parallel the activities of the beta- and the gamma-secretase. ERK1/2 and JNK pathways are involved in this bipartite response, which can lead to neurodegeneration or neuroprotection depending on the cellular and environmental conditions or cooperation with other signalling pathways such as Akt cascade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18255190     DOI: 10.1016/j.neurobiolaging.2007.12.015

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  33 in total

1.  Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease.

Authors:  Steven P Braithwaite; Ralf S Schmid; Dong Ning He; Mei-Li A Sung; Seongeon Cho; Lynn Resnick; Michael M Monaghan; Warren D Hirst; Christian Essrich; Peter H Reinhart; Donald C Lo
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

Review 2.  Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Neurol       Date:  2010-05-05       Impact factor: 5.330

3.  Hippocampal c-Jun-N-terminal kinases serve as negative regulators of associative learning.

Authors:  Tessi Sherrin; Thomas Blank; Cathrin Hippel; Martin Rayner; Roger J Davis; Cedomir Todorovic
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

4.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 5.  Obesity, leptin, and Alzheimer's disease.

Authors:  Edward B Lee
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

6.  Safranal protects against beta-amyloid peptide-induced cell toxicity in PC12 cells via MAPK and PI3 K pathways.

Authors:  Faezeh Rafieipour; Elham Hadipour; Seyed Ahmad Emami; Javad Asili; Zahra Tayarani-Najaran
Journal:  Metab Brain Dis       Date:  2018-11-06       Impact factor: 3.584

7.  Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.

Authors:  Hani S Hafez; Doaa A Ghareeb; Samar R Saleh; Mariam M Abady; Maha A El Demellawy; Hend Hussien; Nihad Abdel-Monem
Journal:  Psychopharmacology (Berl)       Date:  2017-07-22       Impact factor: 4.530

8.  Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis.

Authors:  Jason A Bailey; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  Gene       Date:  2011-06-25       Impact factor: 3.688

Review 9.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

10.  RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment.

Authors:  Nicola Origlia; Chiara Criscuolo; Ottavio Arancio; Shirley ShiDu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2014-06-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.